Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
Information source: Wills Eye
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: Restasis (Drug); Endura (artificial tears) (Drug)
Sponsored by: Wills Eye
Official(s) and/or principal investigator(s):
Marlene R. Moster, MD, Principal Investigator, Affiliation: Wills Eye Glaucoma Research Center
The purpose of this study is to determine whether reducing inflammation of the surface of the
eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase
Official title: Influence of Post-Operative Cyclosporine 0.05% (Restasis) on the Success of Glaucoma Filtering Surgery
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: intraocular pressure
Secondary outcome: ocular inflammation
Continued use of glaucoma drops can alter the outer surface of the eye and result in swelling
and irritation, changing the structure of the eye. This structural change has been found to
be a significant risk factor for the failure of glaucoma surgery. A comparison of how well
patients do after glaucoma surgery depending on whether they use Restasis (the only
prescription medication approved by the FDA for treating dry eye) or artificial tears (which
can be purchased without a prescription) for 6 months following their surgery.
Minimum age: 18 Years.
Maximum age: N/A.
- Patients with uncontrolled glaucoma scheduled for filtering surgery
- Under 18 years of age
- Unable to understand informed consent
Locations and Contacts
Wills Eye Glaucoma Service, Philadelphia, Pennsylvania 19107, United States
Starting date: March 2004
Ending date: November 2007
Last updated: February 24, 2008